




Searching News Database: Shire Pharmaceuticals
HSMN NewsFeed - 18 Jan 2023
NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President
NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President
HSMN NewsFeed - 8 Mar 2016
Medgenics Hires Rick Couch, Ph.D. to Vice President of Chemistry, Manufacturing and Controls
Medgenics Hires Rick Couch, Ph.D. to Vice President of Chemistry, Manufacturing and Controls
HSMN NewsFeed - 9 Feb 2016
Amplyx Pharmaceuticals Expands Management Team and Increases Its Series B Financing to $49.2 Million
Amplyx Pharmaceuticals Expands Management Team and Increases Its Series B Financing to $49.2 Million
HSMN NewsFeed - 8 Sep 2015
Vanda Pharmaceuticals Announces the Appointment of European General Manager
Vanda Pharmaceuticals Announces the Appointment of European General Manager
HSMN NewsFeed - 8 Jul 2015
Synergy Pharmaceuticals Appoints Troy Hamilton as Chief Commercial Officer
Synergy Pharmaceuticals Appoints Troy Hamilton as Chief Commercial Officer
HSMN NewsFeed - 22 Oct 2014
Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors
Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors
HSMN NewsFeed - 31 Jul 2008
Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
HSMN NewsFeed - 3 Apr 2008
Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
HSMN NewsFeed - 17 Jan 2008
Shire Completes Fosrenol(R) Roll-Out in Major European Markets With Launch in Spain
Shire Completes Fosrenol(R) Roll-Out in Major European Markets With Launch in Spain
HSMN NewsFeed - 6 Nov 2007
Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD Stage 3 & 4 Patients
Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD Stage 3 & 4 Patients
HSMN NewsFeed - 24 Sep 2007
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
HSMN NewsFeed - 23 Aug 2007
Cytochroma announces appointment of Gordon Ngan, CFA, MBA as Executive Director, Corporate Development
Cytochroma announces appointment of Gordon Ngan, CFA, MBA as Executive Director, Corporate Development
HSMN NewsFeed - 10 Jul 2007
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
HSMN NewsFeed - 17 May 2007
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
HSMN NewsFeed - 21 Mar 2007
ADDERALL XR(R) - Shire Files Suit Against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf
ADDERALL XR(R) - Shire Files Suit Against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf
HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
HSMN NewsFeed - 21 Nov 2006
Altus Pharmaceuticals Appoints Shire Executive David Pendergast to Board of Directors
Altus Pharmaceuticals Appoints Shire Executive David Pendergast to Board of Directors
HSMN NewsFeed - 16 Nov 2006
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
HSMN NewsFeed - 13 Nov 2006
Taro Receives Marketing Authorization in UK for Etopan XL Tablets 600 mg, Etodolac
Taro Receives Marketing Authorization in UK for Etopan XL Tablets 600 mg, Etodolac
HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
HSMN NewsFeed - 25 Sep 2006
Approval of FOSRENOL in the United Kingdom triggers U.S.$3 million payment to AnorMED
Approval of FOSRENOL in the United Kingdom triggers U.S.$3 million payment to AnorMED
HSMN NewsFeed - 8 Sep 2006
Shire Provides Update on U.S. Marketing Application of MESAVANCE(TM) (mesalamine) With MMX Technology
Shire Provides Update on U.S. Marketing Application of MESAVANCE(TM) (mesalamine) With MMX Technology
HSMN NewsFeed - 24 Jul 2006
Shire's ELAPRASE(TM) (idursulfase) Approved by the Food and Drug Administration (FDA) for Hunter Syndrome
Shire's ELAPRASE(TM) (idursulfase) Approved by the Food and Drug Administration (FDA) for Hunter Syndrome
HSMN NewsFeed - 29 Jun 2006
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
HSMN NewsFeed - 25 May 2006
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
HSMN NewsFeed - 6 Apr 2006
Shire's DAYTRANA(TM) Transdermal Patch Approved by FDA for Treatment of ADHD
Shire's DAYTRANA(TM) Transdermal Patch Approved by FDA for Treatment of ADHD
HSMN NewsFeed - 10 Mar 2006
Shire Announces Status of Ongoing FDA Review of NDA for DAYTRANA(TM) for the Treatment of ADHD
Shire Announces Status of Ongoing FDA Review of NDA for DAYTRANA(TM) for the Treatment of ADHD
HSMN NewsFeed - 3 Mar 2006
Shire Sues Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc.
Shire Sues Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc.
HSMN NewsFeed - 3 Feb 2006
Shire Announces European Filings of SPD476 (Mesalazine) for Treatment of Ulcerative Colitis
Shire Announces European Filings of SPD476 (Mesalazine) for Treatment of Ulcerative Colitis
HSMN NewsFeed - 18 Jan 2006
ADDERALL XR(R) - Paragraph IV Notice Update - Third Notice Letter From Teva Pharmaceuticals USA, Inc.
ADDERALL XR(R) - Paragraph IV Notice Update - Third Notice Letter From Teva Pharmaceuticals USA, Inc.
Additional items found! 113

Members Archive contains
113 additional stories matching:
Shire Pharmaceuticals
(Password required)
Shire Pharmaceuticals
(Password required)